{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:01:33Z","timestamp":1772128893578,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.japh.2023.06.028","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T21:15:33Z","timestamp":1688505333000},"page":"1461-1471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cephalosporins for the treatment of uncomplicated pyelonephritis: A systematic review"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9661-0895","authenticated-orcid":false,"given":"David E.","family":"Zimmerman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Tomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Tomcsanyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Signorella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9839-2510","authenticated-orcid":false,"given":"Courtney A.","family":"Montepara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan R.","family":"Covvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9019-8847","authenticated-orcid":false,"given":"Anthony J.","family":"Guarascio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.japh.2023.06.028_bib1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1056\/NEJMc1801800","article-title":"Acute pyelonephritis in adults","volume":"378","author":"Johnson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.japh.2023.06.028_bib2","first-page":"173","article-title":"Acute pyelonephritis in adults: rapid evidence review","volume":"102","author":"Herness","year":"2020","journal-title":"Am Fam Phys"},{"issue":"3","key":"10.1016\/j.japh.2023.06.028_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/519268","article-title":"Population-based epidemiologic analysis of acute pyelonephritis","volume":"45","author":"Czaja","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.japh.2023.06.028_bib4","first-page":"933","article-title":"Diagnosis and management of acute pyelonephritis in adults","volume":"71","author":"Ramakrishnan","year":"2005","journal-title":"Am Fam Phys"},{"issue":"11","key":"10.1016\/j.japh.2023.06.028_bib5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2165\/00019053-200523110-00005","article-title":"Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy","volume":"23","author":"Brown","year":"2005","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.japh.2023.06.028_bib6","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.japh.2023.06.028_bib7","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/cid\/ciab560","article-title":"Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011 to 2019: rising ESBL strains and impact on patient management","volume":"73","author":"Kaye","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.japh.2023.06.028_bib8","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.japh.2023.06.028_bib9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/003655401750173922","article-title":"Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime","volume":"33","author":"Cronberg","year":"2001","journal-title":"Scand J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.japh.2023.06.028_bib10","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.ijantimicag.2003.09.002","article-title":"Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections","volume":"23","author":"Naber","year":"2004","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.japh.2023.06.028_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A\u00a0double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"Peterson","year":"2008","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.japh.2023.06.028_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/emj.19.1.19","article-title":"Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial","volume":"19","author":"Sanchez","year":"2002","journal-title":"Emerg Med J"},{"issue":"2 Pt 1","key":"10.1016\/j.japh.2023.06.028_bib13","first-page":"734","article-title":"Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis","volume":"171","author":"Talan","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.japh.2023.06.028_bib14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.japh.2023.06.028_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/mdr.2013.0075","article-title":"Impact of extended-spectrum beta-lactamase on acute pyelonephritis treated with empirical ceftriaxone","volume":"20","author":"Lee","year":"2014","journal-title":"Microb Drug Resist"},{"issue":"5","key":"10.1016\/j.japh.2023.06.028_bib17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3346\/jkms.2012.27.5.476","article-title":"Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial","volume":"27","author":"Park","year":"2012","journal-title":"J\u00a0Korean Med Sci"},{"issue":"4","key":"10.1016\/j.japh.2023.06.028_bib18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2174\/1871526520999200727154214","article-title":"Levofloxacin versus ceftriaxone for the treatment of acute pyelonephritis in Iranian adults","volume":"21","author":"Tehrani","year":"2021","journal-title":"Infect Disord Drug Targets"},{"issue":"5","key":"10.1016\/j.japh.2023.06.028_bib19","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3349\/ymj.2015.56.5.1266","article-title":"Comparison of second- and third-generation cephalosporin as initial therapy for women with community-onset uncomplicated acute pyelonephritis","volume":"56","author":"Chang","year":"2015","journal-title":"Yonsei Med J"},{"issue":"4","key":"10.1016\/j.japh.2023.06.028_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106560","article-title":"Comparing outcomes among outpatients treated for pyelonephritis with oral cephalosporins versus first-line agents","volume":"59","author":"Fosse","year":"2022","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.japh.2023.06.028_bib21","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/jac\/dkw035","article-title":"Are first-generation cephalosporins obsolete? A retrospective, non-inferiority, cohort study comparing empirical therapy with cefazolin versus ceftriaxone for acute pyelonephritis in hospitalized patients","volume":"71","author":"Hobbs","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.japh.2023.06.028_bib22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/0897190014568380","article-title":"Clinical impact of discordant prescribing of fluoroquinolones and alternative treatments in Escherichia coli pyelonephritis","volume":"29","author":"Hong","year":"2016","journal-title":"J\u00a0Pharm Pract"},{"key":"10.1016\/j.japh.2023.06.028_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/IDR.S178183","article-title":"Oral sitafloxacin vs intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: a randomized controlled trial","volume":"12","author":"Lojanapiwat","year":"2019","journal-title":"Infect Drug Resist"},{"issue":"12","key":"10.1016\/j.japh.2023.06.028_bib24","doi-asserted-by":"crossref","first-page":"e843","DOI":"10.1016\/j.ijid.2012.07.009","article-title":"A\u00a0prospective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis","volume":"16","author":"Monmaturapoj","year":"2012","journal-title":"Int J Infect Dis"},{"issue":"6","key":"10.1016\/j.japh.2023.06.028_bib25","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/jac\/dkw021","article-title":"Evaluation of the efficacy and tolerance of a short 7 day third-generation cephalosporin treatment in the management of acute pyelonephritis in young women in the emergency department","volume":"71","author":"Moustafa","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.japh.2023.06.028_bib26","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.ajem.2018.08.016","article-title":"Pyelonephritis treatment in the community emergency department: cephalosporins vs. first-line agents","volume":"36","author":"Vogler","year":"2018","journal-title":"Am J Emerg Med"},{"issue":"1","key":"10.1016\/j.japh.2023.06.028_bib27","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12875-022-01816-6","article-title":"Patterns and trends of antibacterial treatment in patients with urinary tract infections, 2015\u20132019: an analysis of health insurance data","volume":"23","author":"Schmiemann","year":"2022","journal-title":"BMC Prim Care"},{"key":"10.1016\/j.japh.2023.06.028_bib28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ajem.2020.09.061","article-title":"Antibiotic prescribing patterns for adult urinary tract infections within emergency department and urgent care settings","volume":"45","author":"Maddali","year":"2021","journal-title":"Am J Emerg Med"},{"issue":"6","key":"10.1016\/j.japh.2023.06.028_bib33","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1128\/AAC.39.6.1240","article-title":"Cefixime penetration in human renal parenchyma","volume":"39","author":"Leroy","year":"1995","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123002418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123002418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:52:41Z","timestamp":1761544361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319123002418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1544319123002418"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2023.06.028","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cephalosporins for the treatment of uncomplicated pyelonephritis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2023.06.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}